News | October 06, 2024
Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Subscribe To Our Newsletter & Stay Updated
